drugset / Trial / NCT02844582

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT02844582

Phase 2 Terminated 2 enrolled University of California, Davis Sanofi · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well cabazitaxel and prednisone work in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start
2017-12-20
Primary completion
2019-06-04
Completion
2019-06-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabazitaxel Other / unclassified Intravenous
Background Prednisone Other / unclassified Oral